银诺医药-B：香港公开发售获5341.66倍认购

Core Viewpoint - The company, Silvernote Pharmaceuticals-B (02591), has successfully completed its global offering, raising approximately HKD 635 million through the issuance of 36.56 million shares at a final price of HKD 18.68 per share [1] Group 1: Offering Details - The global offering consisted of 36.56 million shares, with 10% allocated for the Hong Kong public offering and 90% for international offering [1] - The Hong Kong public offering was oversubscribed by 5,341.66 times, while the international offering was oversubscribed by 10.67 times [1] Group 2: Trading Information - The shares are expected to commence trading on the Hong Kong Stock Exchange on August 15, 2025, at 9:00 AM [1]